vs
Side-by-side financial comparison of Invesco Mortgage Capital Inc. (IVR) and Nurix Therapeutics, Inc. (NRIX). Click either name above to swap in a different company.
Invesco Mortgage Capital Inc. is the larger business by last-quarter revenue ($21.3M vs $13.6M, roughly 1.6× Nurix Therapeutics, Inc.). Invesco Mortgage Capital Inc. runs the higher net margin — 242.2% vs -576.1%, a 818.4% gap on every dollar of revenue. On growth, Invesco Mortgage Capital Inc. posted the faster year-over-year revenue change (55.4% vs 2.2%). Over the past eight quarters, Invesco Mortgage Capital Inc.'s revenue compounded faster (74.2% CAGR vs -9.5%).
Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel targeted protein degradation therapies for cancer, immune disorders and other serious unmet medical needs. Its core pipeline leverages proprietary E3 ubiquitin ligase modulation technology, with operations primarily based in the United States and collaborative partnerships with global pharmaceutical firms.
IVR vs NRIX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.3M | $13.6M |
| Net Profit | $51.5M | $-78.2M |
| Gross Margin | — | — |
| Operating Margin | — | -612.0% |
| Net Margin | 242.2% | -576.1% |
| Revenue YoY | 55.4% | 2.2% |
| Net Profit YoY | 1368.7% | -33.6% |
| EPS (diluted) | $0.72 | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.3M | $13.6M | ||
| Q3 25 | $17.6M | $7.9M | ||
| Q2 25 | $17.7M | $44.1M | ||
| Q1 25 | $18.8M | $18.5M | ||
| Q4 24 | $13.7M | $13.3M | ||
| Q3 24 | $7.5M | $12.6M | ||
| Q2 24 | $8.6M | $12.1M | ||
| Q1 24 | $7.0M | $16.6M |
| Q4 25 | $51.5M | $-78.2M | ||
| Q3 25 | $53.5M | $-86.4M | ||
| Q2 25 | $-23.3M | $-43.5M | ||
| Q1 25 | $19.6M | $-56.4M | ||
| Q4 24 | $3.5M | $-58.5M | ||
| Q3 24 | $40.7M | $-49.0M | ||
| Q2 24 | $-13.5M | $-44.5M | ||
| Q1 24 | $29.1M | $-41.5M |
| Q4 25 | — | -612.0% | ||
| Q3 25 | — | -1157.7% | ||
| Q2 25 | — | -109.7% | ||
| Q1 25 | — | -340.7% | ||
| Q4 24 | — | -486.7% | ||
| Q3 24 | — | -433.8% | ||
| Q2 24 | — | -401.4% | ||
| Q1 24 | — | -272.6% |
| Q4 25 | 242.2% | -576.1% | ||
| Q3 25 | 303.6% | -1094.8% | ||
| Q2 25 | -131.6% | -98.7% | ||
| Q1 25 | 104.4% | -305.4% | ||
| Q4 24 | 25.6% | -440.7% | ||
| Q3 24 | 542.2% | -388.9% | ||
| Q2 24 | -155.9% | -368.4% | ||
| Q1 24 | 415.9% | -250.3% |
| Q4 25 | $0.72 | $-0.83 | ||
| Q3 25 | $0.74 | $-1.03 | ||
| Q2 25 | $-0.40 | $-0.52 | ||
| Q1 25 | $0.26 | $-0.67 | ||
| Q4 24 | $-0.09 | $-0.74 | ||
| Q3 24 | $0.63 | $-0.67 | ||
| Q2 24 | $-0.38 | $-0.71 | ||
| Q1 24 | $0.49 | $-0.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $56.0M | $247.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $797.5M | $538.7M |
| Total Assets | $6.5B | $688.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $56.0M | $247.0M | ||
| Q3 25 | $58.5M | $78.4M | ||
| Q2 25 | $59.4M | $84.3M | ||
| Q1 25 | $42.9M | $75.9M | ||
| Q4 24 | $73.4M | $110.0M | ||
| Q3 24 | $48.3M | $99.0M | ||
| Q2 24 | $58.8M | $116.8M | ||
| Q1 24 | $59.9M | $49.8M |
| Q4 25 | $797.5M | $538.7M | ||
| Q3 25 | $769.6M | $372.3M | ||
| Q2 25 | $709.4M | $447.6M | ||
| Q1 25 | $759.2M | $480.9M | ||
| Q4 24 | $730.7M | $527.0M | ||
| Q3 24 | $857.0M | $376.9M | ||
| Q2 24 | $759.2M | $370.7M | ||
| Q1 24 | $785.6M | $168.7M |
| Q4 25 | $6.5B | $688.1M | ||
| Q3 25 | $6.0B | $522.5M | ||
| Q2 25 | $5.4B | $591.6M | ||
| Q1 25 | $6.2B | $615.0M | ||
| Q4 24 | $5.7B | $669.3M | ||
| Q3 24 | $6.1B | $513.6M | ||
| Q2 24 | $5.1B | $511.0M | ||
| Q1 24 | $5.2B | $312.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $157.1M | $-67.8M |
| Free Cash FlowOCF − Capex | — | $-73.0M |
| FCF MarginFCF / Revenue | — | -537.4% |
| Capex IntensityCapex / Revenue | — | 37.8% |
| Cash ConversionOCF / Net Profit | 3.05× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-263.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $157.1M | $-67.8M | ||
| Q3 25 | $37.3M | $-57.4M | ||
| Q2 25 | $40.6M | $-63.2M | ||
| Q1 25 | $19.3M | $-61.1M | ||
| Q4 24 | $183.2M | $-48.8M | ||
| Q3 24 | $30.8M | $-42.2M | ||
| Q2 24 | $33.0M | $-39.7M | ||
| Q1 24 | $57.5M | $-42.0M |
| Q4 25 | — | $-73.0M | ||
| Q3 25 | — | $-60.1M | ||
| Q2 25 | — | $-65.8M | ||
| Q1 25 | — | $-64.6M | ||
| Q4 24 | — | $-50.9M | ||
| Q3 24 | — | $-44.5M | ||
| Q2 24 | — | $-41.6M | ||
| Q1 24 | — | $-44.8M |
| Q4 25 | — | -537.4% | ||
| Q3 25 | — | -761.3% | ||
| Q2 25 | — | -149.4% | ||
| Q1 25 | — | -349.9% | ||
| Q4 24 | — | -382.8% | ||
| Q3 24 | — | -353.7% | ||
| Q2 24 | — | -344.4% | ||
| Q1 24 | — | -270.3% |
| Q4 25 | — | 37.8% | ||
| Q3 25 | — | 34.3% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 18.9% | ||
| Q4 24 | — | 15.8% | ||
| Q3 24 | — | 18.6% | ||
| Q2 24 | — | 16.0% | ||
| Q1 24 | — | 17.4% |
| Q4 25 | 3.05× | — | ||
| Q3 25 | 0.70× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 52.24× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.97× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IVR
Segment breakdown not available.
NRIX
| Pfizer | $11.9M | 88% |
| Gilead Agreement | $1.7M | 13% |
